Author: Brown, Alex J.

Source: Current Drug Metabolism, Volume 6, Number 7, May 2000 , pp. 701-716(16)

Publisher: Bentham Science Publishers

Abstract:

The wide range of activities now attributed to 1,25(OH)2 D 3 has suggested numerous potential therapeutic applications for this vitamin D hormone, including inhibiting growth of various type of cancer. Unfortunately, the potent calcemic activity of the natural hormone has precluded its use in most cases. Vitamin D analogs with higher therapeutic indices offer renewed hope for treatment of malignancies. The promising analogs currently under study were selected from hundreds of candidates by in vitro screening followed by in vivo testing. The mecha-nism( s) responsible for the greater effectiveness of most of these compounds is not known. Our current understanding of vitamin D physiology and biochemistry suggests that the biological profile of an analog would be determined primarily by its interaction with four classes of proteins: 1) the nuclear vitamin D receptor (VDR) that mediates transcriptional regulation; 2) the metabolic enzymes, primarily the vitamin D-24-hydroxylase but possibly others 3) serum transporters, mainly vitamin D binding protein (DBP), and perhaps lipoproteins; and 4) a new class of receptors that reside in the plasma membrane and mediate rapid, nongenomic responses. This article discusses how the manner in which analogs associate with these proteins can potentially produce selective actions at the tissue, cell and gene level. A thorough understanding of the influence of these analog-protein interactions on the biological profile of vitamin D analogs will be invaluable for the design of future analogs with enhanced target specificity.

Keywords: Vitamin D Analogues; nuclearvitamin D; receptor VDR; D 24 hydrox; vitamin D binding protein DBP; lipoproteins; 25 dihydroxyvitamin D3 1 25 OH2 D3; Translocation; VDR Phosphorylation; Heterodimerization; RXR; DNA Bind; Serum Vitamin D; Binding DBP; Transporters; parathyroid horomone PTH gene transcription; Vitamin D 24 Hydroxylase; hglucocoorticoids; estrone E1; estradiol E2; Nongenomic Activity

Document Type: Research article

Affiliations: 1: Box 8126, 660 S. Euclid, St. Louis, MO 63110, USA

Publication date: 2000-05-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Brown, Alex J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers